Literature DB >> 22303529

The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis).

N Busso1, H-K Ea.   

Abstract

Recent advances have stimulated new interest in the area of crystal arthritis, as microcrystals can be considered to be endogenous "danger signals" and are potent stimulators of immune as well as non-immune cells. The best known microcrystals include urate (MSU), and calcium pyrophosphate (CPP) crystals, associated with gout and pseudogout, respectively. Acute inflammation is the hallmark of the acute tissue reaction to crystals in both gout and pseudogout. The mechanisms leading to joint inflammation in these diseases involve first crystal formation and subsequent coating with serum proteins. Crystals can then interact with plasma cell membrane, either directly or via membrane receptors, leading to NLRP3 activation, proteolytic cleavage and maturation of pro-interleukin-1β (pro-IL1β) and secretion of mature IL1β. Once released, this cytokine orchestrates a series of events leading to endothelial cell activation and neutrophil recruitment. Ultimately, gout resolution involves several mechanisms including monocyte differentiation into macrophage, clearance of apoptotic neutrophils by macrophages, production of Transforming Growth Factor (TGF-β) and modification of protein coating on the crystal surface. This review will examine these different steps.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22303529     DOI: 10.4081/reumatismo.2011.230

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  19 in total

1.  Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation.

Authors:  Payel Sil; Haley Wicklum; Chandler Surell; Balázs Rada
Journal:  Inflamm Res       Date:  2016-11-16       Impact factor: 4.575

2.  Acute pseudogout presenting as an exception to Musculoskeletal Infection Society criteria in total knee arthroplasty: a case report.

Authors:  Julianne M Forlizzi; James M Ryan; Kristen E Galow; Aaron C Shang; Donald R Polakoff
Journal:  AME Case Rep       Date:  2020-07-30

3.  Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation.

Authors:  Christopher J Hall; Leslie E Sanderson; Lisa M Lawrence; Bregina Pool; Maarten van der Kroef; Elina Ashimbayeva; Denver Britto; Jacquie L Harper; Graham J Lieschke; Jonathan W Astin; Kathryn E Crosier; Nicola Dalbeth; Philip S Crosier
Journal:  J Clin Invest       Date:  2018-03-26       Impact factor: 14.808

4.  Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: a comprehensive review.

Authors:  Panchatcharam Parthasarathy; S Vivekanandan
Journal:  Health Inf Sci Syst       Date:  2018-10-08

5.  Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Authors:  Viola Klück; Tim L Th A Jansen; Matthijs Janssen; Antoaneta Comarniceanu; Monique Efdé; Isak W Tengesdal; Kiki Schraa; Maartje C P Cleophas; Curtis L Scribner; Damaris B Skouras; Carlo Marchetti; Charles A Dinarello; Leo A B Joosten
Journal:  Lancet Rheumatol       Date:  2020-04-08

Review 6.  A brief review on in vivo models for Gouty Arthritis.

Authors:  Tulsi Patil; Arun Soni; Sanjeev Acharya
Journal:  Metabol Open       Date:  2021-06-14

Review 7.  The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.

Authors:  Alberto Altomare; Addolorata Corrado; Nicola Maruotti; Daniela Cici; Francesco Paolo Cantatore
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

8.  Epigallocatechin-3-gallate reduces inflammation induced by calcium pyrophosphate crystals in vitro.

Authors:  Francesca Oliviero; Paolo Sfriso; Anna Scanu; Ugo Fiocco; Paolo Spinella; Leonardo Punzi
Journal:  Front Pharmacol       Date:  2013-04-17       Impact factor: 5.810

9.  Phytochemical Compositions and Antioxidant and Anti-Inflammatory Activities of Crude Extracts from Ficus pandurata H. (Moraceae).

Authors:  Huiqing Lv; Xiaoping Zhang; Xuezhi Chen; Zhijun Xie; Changfeng Hu; Chengping Wen; Kezhi Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-26       Impact factor: 2.629

10.  Expression of Caspase-1 Gene Transcript Variant mRNA in Peripheral Blood Mononuclear Cells of Patients with Primary Gout in Different TCM Syndromes.

Authors:  Wan-Tai Dang; Dan Xu; Wen-Guang Xie; Jing-Guo Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.